Exact Sciences Corporation (NASDAQ:EXAS) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET

Company Participants

Erik Holznecht - Manager, Investor Relations
Kevin Conroy - Chairman and Chief Executive Officer
Aaron Bloomer - Chief Financial Officer

Conference Call Participants

Patrick Donnelly - Citi
Tycho Peterson - Jefferies
Andrew Brackman - William Blair
Catherine Schulte - Baird
Matt Sykes - Goldman Sachs
Dan Arias - Stifel
Doug Schenkel - Wolfe Research
Vijay Kumar - Evercore ISI
Dan Brennan - TD Cowen
Jack Meehan - Nephron Research
Michael Ryskin - Bank of America
Puneet Souda - Leerink Partners
Subbu Nambi - Guggenheim

Operator

Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]

Thank you. I would now like to turn the call over to Erik, Manager of Investor Relations. Erik, please go ahead.

Erik Holznecht

Thanks, operator. Thank you for joining us for Exact Science's Second Quarter 2024 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO and Aaron Bloomer, our Chief Financial Officer. Exact Sciences issued a news release earlier this afternoon detailing our second quarter financial results. This news release and today's presentation are available on our website at exactsciences.com.

During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website.

I'll now turn the call over to Kevin.

Kevin Conroy

Thanks, Erik. Our second quarter results show the power of Exact Science's platform and dedication of our world-class team. For the first time, we screened over 1 million people in a quarter with Cologuard for colon cancer, the number two deadliest cancer in the U.S. We tested more patients globally with Oncotype DX than ever before. Expanding and leveraging our platform led to record customer engagement.

During the second quarter, more than 190,000 healthcare providers ordered our preeminent cancer tests. Over 350 health systems and oncology centers utilized Exact Nexus, our proprietary technology platform. We made significant progress toward launching Cologuard Plus, our next-generation Cologuard test and Oncodetect our molecular residual disease test. Our team also advanced several other key pipeline programs, including our blood-based colon cancer screening test and multi-cancer screening tests.